Edgewise Therapeutics is a pre-revenue biotech advancing sevasemten for muscular dystrophies, with the GRAND CANYON pivotal trial in Becker muscular dystrophy representing a key value inflection. However, the company's cash runway appears critically short, wit...
Price trend, volume and key moving averages
Trailing total returns as of 10/10/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.53-13.3% vs -$0.47 | — vs — |
Q2 2026 May 7, 2026 | -$0.46+8.0% vs -$0.50 | — vs — |
Q1 2026 Feb 26, 2026 | -$0.47-9.3% vs -$0.43 | — vs — |
Q4 2025 Nov 6, 2025 | -$0.39+2.5% vs -$0.40 | — vs — |
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve - - Company to host webcast to discuss these findings today at 8:30 a.m. Eastern Time - BOULDER, Colo.
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits.
Hsbc Holdings PLC purchased a new position in shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 91,638 shares of the company's stock, valued at approximately $3,723,000. Hsbc Holdings PLC owned 0.08%
Benchmark EWTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Edgewise Therapeutics, Inc. (EWTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $39.23 | $4.22B | -24.07 | — | — | -34.19% | — | |
| $19.58 | $3.35B | 8.55 | 11.87% | 33.42% | 32.39% | — | |
| $109.30 | $8.99B | -29.62 | -16.72% | -285.41% | -21.5% | — | |
| $11.47 | $1.55B | -3.72 | — | — | -398.21% | — | |
| $30.26 | $6.25B | -10.92 | — | -7585.86% | -69.59% | — | |
| $24.49 | $3.06B | -188.38 | 91.34% | 6.15% | 15.05% | — |
Edgewise Therapeutics, Inc. (EWTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Edgewise Therapeutics, Inc. (EWTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 13, 2026·SEC
Jun 5, 2026·SEC
Get notified when EWTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Edgewise Therapeutics, Inc. (EWTX) stock FAQ — growth, dividends, profitability & financials explained
Edgewise Therapeutics, Inc. (EWTX) reported a net loss of $197.2M for fiscal year 2025.
Edgewise Therapeutics, Inc. (EWTX) has a return on equity (ROE) of -34.2%. Negative ROE indicates the company is unprofitable.
Edgewise Therapeutics, Inc. (EWTX) had negative free cash flow of $159.6M in fiscal year 2025, likely due to heavy capital investments.
